Pharming Group NV
$ 16.80
0.24%
24 Feb - close price
- Market Cap 1,170,436,000 USD
- Current Price $ 16.80
- High / Low $ 17.14 / 16.72
- Stock P/E N/A
- Book Value 0.53
- EPS N/A
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE N/A %
- 52 Week High 21.34
- 52 Week Low 7.50
About
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Analyst Target Price
$31.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-22 | 2025-07-31 | 2025-05-06 | 2025-03-12 | 2024-10-24 | 2024-08-01 | 2024-05-08 | 2024-03-14 | 2023-10-26 | 2023-08-03 | 2023-05-11 | 2023-03-16 |
| Reported EPS | 0.1 | 0.01 | -0.022 | 0.005 | -0.0153 | -0.0177 | -0.1851 | -0.0406 | 0.005 | 0.01 | -0.17 | -0.205 |
| Estimated EPS | -0.125 | -0.0125 | -0.025 | 0.0085 | -0.0025 | -0.002 | 0.007 | 0.0045 | 0.01 | 0.01 | -0.17 | -0.21 |
| Surprise | 0.225 | 0.0225 | 0.003 | -0.0035 | -0.0128 | -0.0157 | -0.1921 | -0.0451 | -0.005 | 0 | 0 | 0.005 |
| Surprise Percentage | 180% | 180% | 12% | -41.1765% | -512% | -785% | -2744.2857% | -1002.2222% | -50% | 0% | 0% | 2.381% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAR
2026-02-23 11:40:16
The Oppenheimer 36th Annual Healthcare Life Sciences Conference, held on February 25-26, 2026, will feature leading healthcare and biotechnology companies discussing pipeline progress and clinical advancements. Companies like Ligand Pharmaceuticals (LGND), Pharming Group (PHAR), Jade Biosciences (JBIO), and Corbus Pharmaceuticals (CRBP) will present their latest developments and upcoming milestones, including financial results, clinical trial updates, and regulatory timelines. Other participants include Olema Pharmaceuticals, Aldeyra Therapeutics, MediWound, iBio Inc., vTv Therapeutics, and Turn Therapeutics, showcasing their respective progress in oncology, ophthalmology, wound care, and diabetes.
2026-02-23 11:06:00
The Oppenheimer 36th Annual Healthcare Life Sciences Conference, held on February 25-26, 2026, will feature leading healthcare and biotechnology companies discussing pipeline progress and clinical catalysts. Companies like Ligand Pharmaceuticals (LGND), Pharming Group (PHAR), and Corbus Pharmaceuticals (CRBP) will present and provide updates on their financial results and upcoming milestones for various drug candidates. The conference provides a platform for strategic dialogue between companies, institutional investors, and analysts.
2026-02-20 00:56:43
Pomerantz LLP is investigating potential claims on behalf of investors of Pharming Group N.V. (NASDAQ: PHAR) following a significant drop in its American Depositary Receipt (ADR) price. This decline occurred after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Pharming's supplemental New Drug Application (sNDA) for Joenja® (leniolisib), citing concerns about potential underexposure in lower-weight pediatric patients and an analytical method issue. Investors affected by the February 2, 2026, stock price fall are advised to contact the law firm to learn about joining a potential class action suit.
2026-02-18 06:27:28
Pharming Group N.V. announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, held virtually on February 25-26, 2026. CEO Fabrice Chouraqui and CMO Anurag Relan will present on February 25th. A webcast and replay will be available on the company's website.
2026-02-18 03:27:32
This article analyzes the momentum shifts for Pharming Group N.v. (NASDAQ: PHAR), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It identifies elevated downside risk due to a lack of additional long-term support signals and provides three distinct AI-generated trading strategies for different risk profiles. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal strengths and key support/resistance levels.
2026-02-17 06:27:53
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Pharming Group N.V. (NASDAQ:PHAR) following a significant drop in its stock price. This decline occurred after the U.S. FDA issued a Complete Response Letter for Pharming's supplemental New Drug Application for Joenja®, citing concerns about potential underexposure in lower weight pediatric patients and an analytical method issue. Shareholders who purchased Pharming securities are encouraged to contact the law firm for more information regarding the investigation.
